MCHM Macrochem (MM)

MacroChem to Host Conference Call and Webcast Will Discuss Clinical Trial Results of Opterone(TM), the First Topical Testosterone Cream LEXINGTON, Mass., July 30 /PRNewswire-FirstCall/ -- MacroChem Corporation (NASDAQ:MCHM), a specialty pharmaceutical company, will announce top-line clinical trial results of Opterone(TM), the first topical testosterone cream, on Tuesday, August 3, 2004. The Company will host a conference call at 9:00 a.m. EDT, following issuance of a press release. The conference call will also be webcast. The webcast will be available to all interested parties through MacroChem's website at http://www.macrochem.com/. To access the webcast, go to the Investor Center page and select the appropriate call under the news and media page. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled webcast. The dial-in number for the conference call is 800-299-7098 for domestic callers and 617-801-9715 for international callers. All callers should use reservation number 94617063 to gain access to the call. About MacroChem MacroChem innovates, develops and commercializes pharmaceuticals administered in novel ways to treat important medical conditions. In addition to Opterone, MacroChem is actively developing EcoNail(TM), a SEPA- enhanced antifungal nail lacquer to treat a common and potentially debilitating nail infection known as onychomycosis. For further information please consult http://www.macrochem.com/ Forward-Looking Statements With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled "Risk Factors" in MacroChem's Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Visit our web site at: http://www.macrochem.com/ Contact: Jessica Morris (LaVoie Group) (781) 596-0200 X101 DATASOURCE: MacroChem Corporation CONTACT: Jessica Morris of LaVoie Group, +1-781-596-0200 ext. 101 Web site: http://www.macrochem.com/

Copyright